12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daclatasvir: Additional Phase IIa data

According to analysts attending the American Association for the Study of Liver Diseases meeting in Boston, an investigator presented data from the open-label Phase IIa AI-444040 trial in 170 non-cirrhotic treatment-naïve patients with HCV genotype 1, 2 or 3 infection showing that 12-week treatment with sofosbuvir plus daclatasvir without ribavirin led to an SVR4 rate of 98%. Partner Gilead Sciences Inc. (NASDAQ:GILD, Foster City, Calif.) deferred to Bristol-Myers on the data, while BMS could not be reached for details. In an abstract for the trial, the companies also reported that 24-week...

Read the full 441 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >